Overview

• U.S. precision cardiology RNA therapeutics firm's Q1 collaboration revenue surged yr/yr after spin-off

• Company launched as independent public entity after spin-off from Avidity Biosciences and Novartis acquisition

• Q1 operating expenses rose, driven by clinical trial preparations and public company launch costs

Outlook

• Company expects to submit IND for ATR 1072 in H2 2026

• Atrium plans to initiate Phase 1/2 trial for ATR 1072, pending regulatory clearance

• Company expects to file IND for ATR 1086 in 2027, with IND-enabling studies starting in 2026

Result Drivers

• MILESTONE PAYMENT - Q1 collaboration revenue was mainly driven by a $15 mln milestone payment from Bristol Myers Squibb for delivery of a development candidate

• R&D INVESTMENT - Higher R&D expenses reflected clinical trial preparations, IND-enabling activities, and development of research capabilities

• PUBLIC COMPANY COSTS - G&A expenses increased due to employee-related costs, professional fees, and expenses tied to launching as a public company

Company press release: ID:nPn47J0Lva

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "buy"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Atrium Therapeutics Inc is $25.00, about 88% above its May 13 closing price of $13.30

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.